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Introduction
There has been great interest in exploiting simple MALDI MS profiling for the analysis of crude or little purified human serum or plasma samples for clinical diagnostics [1] [2] [3] . However, through the many studies that have been conducted in this area it has become apparent that there are far more challenges related to its applicability to disease diagnosis than initially thought. The technical bias in the analytical read-out and the ultimate sensitivity and diagnostic accuracy of MALDI MS profiling are of major concern [4] [5] [6] [7] . The wide range of abundances and the complexity of the endogenous molecular components in blood further aggravate the analytical situation 2 . However, there have been now further reports substantiating the claim that MALDI MS profiling can indeed be a tool for disease (outcome) classification 8 and biomarker discovery 9 .
Thus, it is surprising that little is known about most of these potential biomarkers as typically no structural identification is undertaken. This presents a serious limitation for alternative quantification and validation of potentially discriminatory peaks and restricts biomarker assay development, including immunoassays, that might potentially overcome some of the above analytical limitations of MALDI MS profiling.
MALDI MS profiling focuses on the reproducible, rapid and inexpensive acquisition of MS peak patterns that can be used for discriminative analysis as needed in population screening or clinical triage. Thus, it is different to in-depth analyses of the human blood serum or plasma where peak identification is an objective and many thousands of peptides and proteins have been identified [10] [11] [12] .
As with in-depth analyses, peptide identification of MS profile peaks is ideally undertaken at the same time as MS profiling with the same sample on the same instrument, using the MS profile for precursor ion determination and directly switching to MS/MS mode for peptide sequencing. Employing MALDI, however, peptide sequencing is more challenging and usually less sensitive and informative for identification purposes than ESI-LC-MS/MS. Thus, the reported long lists of identified peptides or proteins present in serum or plasma are typically based on ESI-LC-MS/MS (mostly in combination with extensive pre-fractionation) and without any relation to MALDI MS profiles, including the lists that provide identifications in the commonly recorded low molecular weight range of these profiles, i.e. <10 kDa [13] [14] [15] . Indeed, only a few identifications of MALDI MS profile peaks have been reported so far. The most comprehensive list of peptide identifications obtained from human blood serum and related to MALDI MS profile peaks was reported by Villanueva et al. 16 , although it provides only identification of peaks below 4 kDa. For blood plasma, Koomen et al. reported a list of 249 sequenced plasma profile peptides with a maximum mass of 5.2 kDa 17 .
Materials and methods
Venous blood samples were collected from healthy persons recruited at different centres as part of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) or United Kingdom Ovarian Cancer Population Study (UKOPS) (for details see Timms et al., Clin. Chem., in press). The entire study was approved by the local ethics committee and written informed consent was obtained from all donors.
For UKOPS, blood was collected in 10mL-Vacutainer ('red-top') tubes (Becton Dickinson, Oxford, UK; #367985). After phlebotomy, the tubes were inverted 5 times and left at room temperature in a vertical position to clot for 1 hr. Samples were then placed on ice for no more than 2 hrs, centrifuged at 1,500 g for 10 min at room temperature, aliquoted into sterile 10mL-tubes (Sarstedt, Leicester, UK) and frozen at -80°C. For UKCTOCS, different consumables were used and the clotting time was between 8 and 56 hours before spinning, strawing and freezing. All samples were transported to the Institute for Women's Health Laboratory at UCL on dry ice and thawed at room temperature for 30 min. The samples were then mixed by gentle inversion and aliquoted into bar-coded straws, re-frozen at -80°C for 24 hours and then transferred to liquid N2 for long-term storage.
For initial MALDI-TOF MS profiling, serum samples were taken from long-term storage and prepared according to a protocol we have reported elsewhere (see 5 for details). Briefly, polypeptides were enriched from 5 µL of serum using a semi-automated protocol based on reversed phase pre-packed tips (C18 ZipTips ® ). A CyBi ® -Disk robot (CyBio AG, Jena, Germany) equipped with a 96-piston head for 25µL-tips was adapted and used for this purpose. After C18 ZipTip ® purification, enriched polypeptides were eluted from the ZipTips ® , and 2 µL from the eluate were mixed with CHCA matrix and spotted onto a 600µm-AnchorChip target plate (Bruker Daltonics, Bremen, Germany) for analysis on an Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics), using FlexAnalysis v3.0 and ClinProTools v2.1 software (Bruker Daltonics) for further data analysis. The remaining 5 µL of the eluate were immediately stored at -80C until being used for further analysis.
Peak identifications were obtained from the same sample eluates used for MALDI MS profiling, by pooling 96 single ZipTip ® eluates and using three different methods: (i) MALDI MS/MS, (ii) ESI MS/MS and (iii) off-line LC fractionation and ESI MS/MS with or without tryptic digestion. Additional MALDI MS profiles were taken throughout the sample preparation after each essential step in order to link the MALDI MS profile peaks with the obtained peak identification.
For peak identification using MALDI MS/MS, the pooled eluates were mixed in a ratio of 1:1 (v:v) with either 5 mg/mL α-cyano-4-hydroxycinnamic acid (CHCA) or 50 mg/mL 2,5-dihydroxybenzoic acid (DHB) matrix prepared in 50% acetonitrile (ACN) / 0.1% trifluoroacetic acid (TFA) and spotted onto a MALDI target plate for analysis on a Q-TOF Premier (Waters, Manchester, UK) equipped with a 337nm-UV-MALDI source.
For peak identification using ESI MS/MS, the pooled eluates were first dried, then resuspended in 50% ACN / 0.1% formic acid (FA) and sprayed using a Nanomate HD (Advion Biosciences, Ithaca, USA) as nanoESI ion source in front of the Q-TOF Premier. A positive voltage of 1.7 kV was applied to the chip and the flow rate was kept constant at about 80 nL/min. At this flow rate, a sample volume of 10 µL provided stable static electrospray for at least 2 hrs.
For peak identification using the more complex sample processing of off-line LC fractionation and ESI MS/MS, serum fractionation was first carried out, using an Agilent 1100 LC system (Agilent Technologies inc., Santa Clara, USA). A volume of 100 µL of the pooled serum sample eluates was loaded onto a HiChrom ACE C18 column (2.1mm ID, 150 mm length) (HiChrom Ltd., Reading, UK). The column was initially equilibrated with 5% ACN / 0.1% FA. The elution was achieved using a binary solvent gradient of 5% ACN / 0.1% FA to 70% ACN / 0.1% FA at a flow rate of 100 µL/min over 90 min, and finally up to 95% ACN / 0.1% FA in 10 min. The UV detection was set at 214 nm and fractions were collected at a rate of 1 per minute. The fractions were then dried and resuspended in 40 µL of 50% ACN / 0.1% FA. From each resuspended fraction a volume of 15 µL was taken for chip-based nanoESI analysis using the Nanomate and Q-TOF Premier, 2 µL were used for MALDI-TOF analysis using the Ultraflex and the remaining volume was dried before being resuspended with a 15µL-trypsin solution (100 ng trypsin in 100 mM ammonium bicarbonate, pH 8.5). The resuspended solutions were thoroughly mixed and incubated overnight at 37C. Finally, the digested fractions were subjected to automatic cleaning using C18 ZipTips ® according to the protocol detailed above for MALDI-TOF MS profiling except that the elution step which was performed using 10 µL of 50% ACN / 0.1% FA. The purified digested fractions were then loaded on the Nanomate system and nanoESI MS/MS data were collected using data dependent acquisition. Identification of peptides was performed by searching against the human protein sequence library in NCBInr (v20081128, 216937 sequences) using the Mascot search engine (Matrix Science, London, UK). The searches were performed choosing "none" for digestion enzyme and with a mass tolerance of 0.1 Da for parent ions and 0.2 Da for fragment ions. "Ammonia-loss (N-term C)", "Deamidated (NQ)", "Dehydrated (N-term C)", "Oxidation (M)", "Phospho (ST)", and "Phospho (Y)" were set as variable modifications.
GPMAW software v7.10 (Lighthouse data, Odense, Denmark) was used to match accurate mass data obtained from undigested samples with theoretical peptide masses of protein hits obtained from the MASCOT analysis of the MS/MS data of the digested fractions. Isotope pattern software v3.0 (Bruker Daltonics) was used for the comparison of experimental isotopomer distributions with the theoretical distribution from putative peptide identifications and the UniProt and NCBI protein databases were used to extract additional information for substantiating or rejecting putative identities, e.g. information with regard to alternative splicing, prosequence cleavage, disulfide bridges and post-translational modifications.
Results and Discussion
MALDI-TOF MS profiling of 60 serum samples revealed 108 aligned peaks within the combined UKCTOCS and UKOPS serum sample set, using an S/N ratio above 5 (Supplemental Table S1 ). With the threshold set at S/N > 3, the number of common peaks was 156. Despite the high number of common peaks, the different sample collection and handling protocols for the UKOPS and UKCTOCS sample sets resulted in markedly different MALDI MS profiles (Figure 1) . Most of the peak intensities of the 108 common peaks were significantly different between the UKCTOCS and UKOPS samples (Supplemental Table  S1 ). Thus, serum samples from both sample sets were employed in an effort to identify as many profile peaks as possible using the higher mass accuracy and sequencing capability of MALDI Q-TOF instrumentation.
Many of the peak identifications were obtained by direct switching from MALDI MS to MALDI CID MS/MS, analysing the precursor ions determined in the MALDI MS profile. This approach provided a total of 36 identities through MASCOT searching (Supplemental Table  S2 ). The average mass accuracy of the precursor ion mass measurements was 13 ppm. The next approach was using the same samples for nanoESI MS/MS analysis without complex sample processing such as enzymatic digestion or fractionation. A straightforward change of the solvent system made the samples amenable for nanoESI analysis via direct infusion using the chip-based Nanomate system. Similarly to the MALDI analysis, MS profile spectra were first acquired and MS/MS analysis of the precursor ions of the MS profile provided their identity. In this approach, the MALDI and ESI MS profiles were compared to match peaks unambiguously and a total of 16 peaks were identified, of which 6 could not be identified by earlier MALDI MS/MS analysis.
Next, the serum sample eluates were fractionated by off-line C18 reversed phase chromatography and the fractions were analysed by chip-based nanoESI as before. Although LC fractionation was employed, no further advanced sample processing was applied such as depletion or multi-dimensional separation strategies, which have been typically used in previous reports where 200 to 400 peptides were identified [13] [14] [15] 17 . In contrast to these reports, the objective of our fractionation strategy was to enhance mass spectrometric analysis of the profile peaks without changing the overall composition to a degree that would make the assignment of the identities too uncertain. Thus, we also monitored the change of the MALDI MS profile after fractionation by comparing the prefractionation MALDI MS profile with the MALDI MS (and ESI MS) profiles of each fraction. The fractions were then analysed by chip-based nanoESI MS/MS and the MS/MS data of each precursor ion was searched against the human subset of the NCBInr protein database using MASCOT, which resulted in an additional 28 identities and another 9 confirmations of identities obtained by the two earlier approaches without LC fractionation.
Unfortunately for peaks above m/z 4,500, none of these approaches led to unambiguous peptide identification. The collected LC fractions were therefore further processed by performing tryptic in-solution digestion with subsequent purification as employed for MALDI-TOF MS profiling. The digested fractions were analysed by chip-based nanoESI MS/MS and the MS/MS data of each fraction was combined and searched against the human subset of the NCBInr protein database using MASCOT. For each fraction, the protein hits from these searches were then used to search for peptide sequences with a theoretical mass that was within 50 ppm of the experimental value of the previously recorded profile peaks from the undigested fractions. In addition, any putative matches were further interrogated by their isotopomer distribution, their known post-translational modifications and the likelihood of occurrence derived from their structural and functional information in protein databases. For instance, any peptide sequences that stretched over a pro-sequence cleavage site were dismissed. Where possible, fragment ion spectra from the previous methods were also used to substantiate putative identities. Overall, this approach led to an additional 11 peak identities.
In total, more than 80 polypeptides were identified with high confidence, representing peptides from 13 different but highly abundant proteins (see Supplemental Table S2 ). Among these there were three full length proteins, Apoliprotein CII (Apo CII), Apolipoprotein CIII (Apo CIII) and Connective tissue-activating peptide III (CTAP-III). The peaks at m/z 1547 and 1616 were clearly identified by both MALDI MS/MS and ESI MS/MS without LC fractionation, and correspond to Fibrinopeptide A fragments phosphorylated at serine (see Supplemental Figure S1 ). Interestingly, many of the Fibrinopeptide A/B peaks and others show a loss of 17 Da (ammonia) and sometimes of water. Some of the identified peptides/proteins were found to correspond to oxidised forms already identified. These were excluded from the list since many of these did not appear in the MALDI MS profiles and were most likely products obtained from the sample handling. This clearly shows that the MS peaks/profiles can substantially change with complex sample preparation methods, underlining the need for careful profile peak identification that is different to peptide identification of in-depth proteomic serum analyses.
A detailed comparison of our peak list with the peak lists reported by Villanueva et al. 16 and Peng et al. 18 shows that the lists are complementary rather than redundant (see Figure 2 and Table 1 ). It is worth noting that although the number of identified peaks from this study is comparable to the number reported by Villaneuva et al. 16 , only about 30% (25 peaks) are common between the two lists (Figure 2) . Furthermore, the present study was able to identify nine polypeptides in the mass range of 4 -10 kDa, three times as many as reported so far. However, within this mass range there were many more polypeptides for which the parent protein was identified after digestion but the data was inconclusive for assigning single identities to the MALDI MS profile peaks.
A comparison with a list of plasma peptide identifications reported by Koomen et al. shows that again only about 30% (25 peaks) are common. This, however, constitutes only about 10% of the earlier published plasma peptide list which comprises 249 peptide identifications, reflecting the inherent difference between blood plasma and serum. Interestingly, none of the identifications up to a mass of 1,200 Da are shared. In the serum profiles, these are mostly Fibrinogen peptides. The higher signal intensities of Fibrinogen peptides in serum profiles have been reported previously 19 .
Combining this peak list with the lists from Villanueva et al. 16 and Peng et al. 18 increases the number of identified polypeptides of MALDI MS serum profiles to 139. This provides an extensive list of peptide identifications obtained from human blood serum that can be used for provisional identification of MALDI MS profiling peaks below 10 kDa through simple comparison. Furthermore, this will allow, by quick comparison of MS profile and/or MS/MS data, the identification of many potential biomarkers commonly listed in reports without identification and thus, facilitate biomarker validation. Figure S2 ). These fragmentation spectra were typical for phospholipids and their identification was carried out by comparing their accurate masses (within 10 ppm) to the calculated masses obtained from the LipidMaps database (www.lipidmaps.org). The presence of ion fragments at m/z 86.10, 104.11 and 184.07 in all MS/MS spectra is characteristic for choline, H2O-choline and phosphocholine, respectively (see Figure S2 and Table S3 ), and confirmed that these peaks are associated with phosphocholine lipids.
MALDI and ESI MS/MS analysis of some of the MALDI MS profiling peaks resulted in MS/MS spectra different to those usually found for peptides (
Interestingly, a comparison with a recently published list of endogenous serum peptides that were obtained by extensive prefractionation and ESI-MS/MS shows that more than 40% of the fibrinogen (P02671) peptides in Table 1 were not identified despite the much higher number of identified peptides (>1000) obtained in that study 20 . Other comparisons including lists of endogenous plasma peptides 21 and other proteins showed similar results. In addition, none of these lists include any post-translational modifications (PTMs), and only recently a few phosphorylated endogenous serum peptides were reported 22 . The presented list is based on MALDI MS profile peak identification and as such includes PTMs as well as other non-peptidic components. The focus on MALDI MS profile peak identification also provides an additional and decisive advantage. While other lists might provide many more endogenous peptides, these are not linked to MALDI MS profiling. As a result entries cannot be ranked according to their signal intensity in MALDI MS profiles and many of the entries will have the same mass value within a given mass tolerance. For instance, the above comparison (based only on fibrinogen peptides) reveals that the profile peak at m/z 1518.7 would have been wrongly assigned using the more extensive list of endogenous serum peptides published by Bakun et al. 20 . In the latter, the peptide at the corresponding mass was identified as NRGDSTFESKSYK (cf. Table 1 ). In the same list, there is no entry for the serine-phosphorylated peptide DSGEGDFLAEGGGV or for its associated peptide that has lost phosphoric acid, which has the same mass value as NRGDSTFESKSYK within a tolerance of 25ppm. In addition, the peptide entries for the profile peak at m/z 1309.6 would have led to an ambiguous identification of either SSSYSKQFTSST or DSGEGDFLAEGGGV, again assuming a mass accuracy of around 25ppm or more. Even at 10ppm most fibrinogen peptides are not unique for their respective mass value. For instance, there are seven fibrinogen peptides with exactly the same m/z value of 1206.57. The above analysis clearly shows that any list of endogenous serum peptides can only be useful for MALDI MS profiling if the peak identifications can be directly linked to the MALDI MS profiles.
In conclusion, the dataset presented provides the identification of more than 90 serum MALDI MS profiling peaks with little overlap with already published datasets. The more than 80 identified polypeptides originate from only 13 proteins, mainly Fibrinogen alpha and beta chain (total of 48). Complementary to other published lists this dataset also provides the identification of very low molecular weight (< 1 kDa) peaks often associated with phospholipids and peaks above 5 kDa. Together with previously published data the most comprehensive MALDI MS serum profiling list consisting of 148 peak identifications is now available (see Table 1 ). Averaged MALDI-TOF mass spectra of human serum samples collected for UKCTOCS (upper panel) and UKOPS (lower panel) and obtained from purifications of 5μL-aliquots using pre-packed C18 ZipTips ® . Averaged mass spectra were generated by ClinProTools software v2.1 after baseline subtraction, smoothing, normalisation and peak realignment. 
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